Axial Biotherapeutics today announced the launch of the $19 Company. Series 15 million Financing round The company draws on the groundbreaking work of the scientific founder, Professor Sarkis Mazmanian, Ph.D. D. D. Using intestinal microbiome to help treat diseases and disorders of the central nervous system (CNS) Dr. Dr. Mazmanian, Louis & Nelly Soux Professor of Microbiology, Division of Biology & Biological Engineering, California Institute of Technology (Caltech), is a leader in the field of interaction between the intestinal microbiome and the brain as it relates to neurological disorders. Dr. Dr. Mazmanian has published his groundbreaking research in journals including Nature, Science and Cells. The Mazmanian Laboratory was among the first to demonstrate disease-modifying effects in mouse models of autism spectrum disorders (ASDs) through novel and proprietary microbiome interventions. Axial will leverage these findings to build a microbiome discovery platform targeting the intestinal brain axis that provides an opportunity to generate a diverse range of new therapies for patients with neurological disorders and disorders.
‘The discovery that changes in the intestinal microbiome can cause neurological diseases is a paradigm shift and opens up entirely new possibilities for the treatment of patients. I look forward to working with the Axial team to translate our breakthrough discoveries in the laboratory to patients in need. ”
Tweet this one
Series A funding was led by the Longwood Fund and the Domain Associates The financing also included Kairos Ventures, Heritage Medical Systems and a group of high net worth individuals based in Southern California.
In conjunction with the funding, Axial Biotherapeutics announced the appointment of David H. Donabed’s, Ph. D. D. , as Chief Executive Officer and Director of the Board The additional members of the Axial Board include James C Blair, Ph.D. D. D. Domain Associates Partner, Michelle Dipp, M D. D. Ph, Ph. D. D. , Partner, Longwood Fund, and Sarkis Mazman, Ph. D. D. Caltech, man.
‘I look forward to developing this world-class science into treatments that have the potential to help patients with limited treatment options,’ said David H. Donabed’s, Ph. D. D. , Co-founder and CEO of Axial Biotherapy ‘There is evidence that the intestinal microbiome is involved in brain development and neurological health, and we believe that we are at the forefront of generating new avenues for microbiome-targeted therapeutic interventions in multiple neurological diseases and disorders. ”
Axial has licensed exclusive, worldwide intellectual property rights covering the novel and proprietary class of CNS biotherapeutics from the Mazmanian Laboratory at Caltech. Axial will focus on translating these discoveries into a unique class of microbial-targeted biotherapeutics that could become breakthrough therapy for a variety of neurological diseases and disorders, including ASD and Parkinson’s Disease.
‘By examining the biological link between the intestinal microbiome and the brain, we are discovering pathways and mechanisms that can be used to develop novel treatment options for vastly underserved diseases,’ said Sarkis Mazmanian, Ph.D. D. D. , Co-founder of Axial Biotherapy ‘The discovery that changes in the intestinal microbiome can cause neurological diseases is a paradigm shift and opens up entirely new possibilities for the treatment of patients. I look forward to working with the Axial team to translate our breakthrough discoveries in the laboratory to patients in need. ”
David H’s Donabed’s, Ph. D. D. will serve as Chief Executive Officer and Member of the Board of Axial Biotherapeutics Dr. Dr. Donabedian is a successful business development and strategy executive with extensive leadership experience. Dr. Dr. Donabedian has a record of building companies, most recently as a Venture Partner at the Longwood Fund. Before joining Longwood, Dr. Donabedian has held various leadership roles in biopharmaceutical companies, including AbbVie and GSK. In AbbVie, Dr. Donabedian served as Vice President & Global Head of Ventures and Early Stage Collaborations, where he led a global team that completed significant transactions across multiple therapeutic areas and development stages. Before AbbVie, Dr. Donabedian served as Global New Deal Strategy and Development Vice President at GlaxoSmithKline and Senior Manager at Accenture’s Strategic Services Consulting Group. He holds a BA in chemistry in St. Anselm College, Ph.D. D. D. Polymer Chemistry from the University of Massachusetts Lowell and an MBA from the University of North Carolina. He currently serves on the board of Alcyone Life Sciences, a privately held CNS company that he co-founded.
About Axial Biotherapy
Axial Biotherapeutics is a biopharmaceutical company that uses the link between the human intestinal microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life of people with neurological diseases and disorders.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Axial%20Biotherapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
